Previous 10 | Next 10 |
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor co...
Vaxxinity Inc. (VAXX) is expected to report $-0.14 for Q3 2023
2023-11-08 08:56:45 ET More on Vaxxinity Seeking Alpha’s Quant Rating on Vaxxinity Historical earnings data for Vaxxinity Financial information for Vaxxinity For further details see: Vaxxinity GAAP EPS of -$10.00
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We co...
2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global (FBYD) +145% . American Oncology Network ( AONC ) +53% . Akso Health Group ( AHG ) +23% . Vigil Neuroscience ( VIGL ) +20% . NuScale Power Corporation ( SMR )...
2023-10-06 10:35:53 ET More on Health Care Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities: ...
2023-08-31 17:19:31 ET Gainers: Nutanix ( NTNX ) +13% . Intuitive Machines ( LUNR ) +9% . NGM Biopharmaceuticals ( NGM ) +7% . Vaxxinity ( VAXX ) +5% . NANO-X IMAGING ( NNOX ) +5% . Losers: Jet ( JTAI ) -4% . ...
2023-08-10 14:18:01 ET Vaxxinity press release ( NASDAQ: VAXX ): Q2 GAAP EPS of -$0.11. As of June 30, 2023, Vaxxinity had $56.1 million of highly liquid assets, including $37.1 million of cash and cash equivalents, $18.8 million of short-term investments, and $0.2 mi...
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311 could offer multiple competitive advantages over licensed ...
CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “Vaxxinity...
News, Short Squeeze, Breakout and More Instantly...
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological ...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...